Trial reportEuropean journal of nuclear medicine and molecular imaging2024
Dosimetry and pharmacokinetics of [
Trial report in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02592707 (An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas.Frontiers in medicine · 2025Pooled it
- Malignancy Detection Rates of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Targeted βJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Increased progression free survival with radiolabelled somatostatin receptor antagonist versus standard peptide receptor radionuclide therapy in patients with somatostatin receptor positive tumours.European journal of nuclear medicine and molecular imaging · 2026Article
- Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026Review
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.Journal of neuroendocrinology · 2025Review
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- Comparison of the tolerability ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 8 countries.
Funding
Abstract
purposeTo evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [
methodsThis study was part of a phase I/II trial of [
resultsIn all evaluated organs, maximum [
conclusion[
trial registrationNCT02592707. Registered October 30, 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.